Welcome to the
Biogen Newsroom

Find out how we are pioneering neuroscience to transform lives and support our communities by exploring the latest news releases, Biogen initiatives, company statements and exclusive stories.

Latest News

June 10, 2021
Biogen Announces Investor Day on September 21, 2021

CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Biogen Inc.   (Nasdaq: BIIB) announced today that it will hold an Investor Day focused on its broad pipeline across neuroscience and related therapeutic adjacencies. The event will be webcast live on September 21, 2021 at 10:00 a.m. ET.

June 10, 2021
New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen’s Commitment to Innovation in SMA Therapy

New data analysis suggests an investigational higher dose of SPINRAZA may lead to clinically meaningful improvements in motor function A NURTURE study analysis shows 92 percent of children who initiated SPINRAZA treatment as pre-symptomatic infants maintained the ability to swallow after

June 7, 2021
A Letter from Biogen’s CEO on ADUHELM

Today, on behalf of my Biogen colleagues, I am incredibly humbled to share that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELMTM (aducanumab-avwa), the first-ever therapy to address a defining pathology of Alzheimer’s disease—amyloid beta plaque.  We come

See Our Latest Tweets

Biogen Statements
Biogen Statements

See the latest news and statements from Biogen to stay up to date on our progress and learn about new company initiatives.

Read More
Annual Report
Annual Report

Review our annual reports to see performance highlights, financials, SEC filings, stock information and more.

Read More
Sustainability Report
Sustainability Report: 2020 Year in Review

Learn more about what actions we are taking to deliver on our bold and unwavering commitments to our patients, employees, environment and communities.

Read More

Innovation in Alzheimer's

We remain focused on furthering Alzheimer’s disease research and treatment. Explore the latest information, news and stories about Alzheimer’s disease at Biogen.

Alzheimer

The Alzheimer’s Puzzle: Unlocking the Science

From imaging that enables us to see amyloid and tau in the brain and determine whether potential therapeutics reach their targets, to one big leap of faith that antibodies can get into the brain, our scientists are not giving up on solving the Alzheimer’s puzzle.

health
Healthy Climate, Healthy Lives™

Biogen invests $250 million in a 20-year initiative to accelerate action on the greatest challenges of our time: climate, health and equity.

Read More
Diversity
Diversity, Equity and Inclusion

We are committed to building on our culture of inclusion and belonging that reflects the communities where we operate and the patients who we serve.

Read More
Corporate Responsibility

Our Commitment to Corporate Responsibility

Our impact goes beyond our medicines as we strive to improve patient health outcomes, solve social and environmental challenges, and help our employees thrive.

Read More

Request Multimedia Resources

For Media Professionals

Access Biogen logos, infographics, images, videos and more. Our media relations team will help you find exactly what you need.

Get in Touch

Get Biogen Updates Delivered to Your Inbox

Subscribe to receive news and stories from Biogen that reflect both our dedication to transforming lives through pioneering neuroscience as well as our commitment to our communities.”

Sign Up for Biogen Alerts
Be the first to know about the latest news, updates, events and SEC Filings by signing up for Biogen email alerts.